Study of Genetic Factors in Acetaminophen-Induced Liver Injury in Chinese Patients

What this Trial Is About

Researchers are investigating genetic factors that might make some people in the Chinese population more likely to develop liver injury after taking acetaminophen APAP, a common pain reliever. This study compares individuals who have experienced drug-induced liver injury DILI from APAP with those who have not, aiming to find genetic differences that could explain susceptibility. Previous genetic findings from U.S. populations did not apply well to Chinese individuals, so this research focuses specifically on a Chinese group. Participants are divided into two groups based on whether they developed liver injury after APAP use. Inclusion requires a clear history of acetaminophen ingestion or positive testing for its components, along with liver enzyme levels ALT or AST of 1000 IUL or higher, and a causality score indicating APAP caused the injury. The study uses gene analysis methods, including genotyping over two million marker sites and immune gene typing, to identify genetic variations associated with liver injury risk. Strict protocols and quality controls ensure accurate data collection and management. During the study, participants provide clinical information and samples for genetic testing. Researchers collect data on acetaminophen exposure, liver enzyme levels, and causality assessments. The main outcome is the difference in genetic polymorphisms between those with and without liver injury, measured over two years. Data is carefully monitored and analyzed using statistical software to understand genetic links to APAP-induced liver injury. The study aims to improve understanding of genetic risks in this population and potentially guide safer medication use.

Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study